Lung Cancer
Volume 55, Issue 1 , Pages 89-94 , January 2007

Once-weekly epoetin beta (30,000IU) in anemic patients with lung cancer receiving chemotherapy

Received 18 July 2006 ,Revised 25 September 2006 ,Accepted 26 September 2006.

References 

  1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293–2306
  2. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol. 1998;25(Suppl. 7):43–46
  3. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol. 1997;34(Suppl. 2):4–12
  4. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer fatigue forum. Ann Oncol. 2000;11:971–975
  5. Dillon E, Kelly J. The status of cancer fatigue on the island of Ireland: AIFC professional and interim patient surveys. Oncologist. 2003;8(Suppl. 1):22–26
  6. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616–1634
  7. Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E, et al. Standards, options and recommendations for the management of non-small cell lung carcinoma patients. Bull Cancer. 2003;90:151–166
  8. Langer CJ, Choy H, Glaspy JA, Colowick A. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer. 2002;95:613–623
  9. Morère J-F. Role of epoetin in the management of anaemia in patients with lung cancer. Lung Cancer. 2004;46:149–156
  10. Glimelius B, Linné T, Hoffman K, Larsson L, Svensson JH, Näsman P, et al. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol. 1998;16:434–440
  11. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol. 1998;9:255–260
  12. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol. 1998;15:174–182
  13. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol. 2002;20:2486–2494
  14. Boogaerts M, Coiffier B, Kainz C Epoetin beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer. 2003;88:988–995
  15. Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990;322:1693–1699
  16. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phases I and II clinical trial. N Engl J Med. 1987;316:73–78
  17. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol. 2003;122:386–393
  18. Marangolo M, Láng I, Beato C, Colomer R, Ukarma L. Breast cancer–anemia and the value of erythropoetin (BRAVE): preliminary results from a study of the efficacy of epoetin beta 30000IU once weekly in patients with metastatic breast cancer receiving chemotherapy. Eur J Cancer Suppl. 2005;3:388;(abstract 1347)
  19. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P Anemia Study Group. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer. 2001;37:1617–1623
  20. Barrett-Lee PJ, Ludwig H, Birgegard G, Bokemeyer C, Gascon P, Kosmidis PA, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European cancer anaemia survey. Oncology. 2006;70:34–48
  21. Denison U, Baumann J, Peters-Engl C, Samonigg H, Krippl P, Lang A, et al. Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2003;79:347–353
  22. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Österborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201–2216
  23. Rizzo D, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083–4107
  24. Hardut D, Wiesenberger K, Minar W, Pirker R. Epoetin beta in patients with lung cancer receiving chemotherapy. Lung Cancer. 2003;41(Suppl. 2):S264;(abstract P-682)
  25. Hardut D, Wiesenberger K, Minar W, Pirker R. Epoetin beta (NeoRecormon®) in patients with lung cancer receiving chemotherapy. In: Poster presented at the proceedings of 10th world conference on lung cancer 2003. 2003;
  26. Zarogoulidis K, Papagiannis A, Ziogas E, Fahantidou E, Dermitzakis G, Gioulekas D, et al. Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer. Eur J Cancer. 1997;33:2428–2431
  27. Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer. 1999;80:396–402
  28. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002;3:180–190
  29. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211–1220
  30. Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, et al. A randomized comparison of every 2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung or gynaecologic cancer. Oncologist. 2004;9:696–707
  31. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23:2606–2617
  32. de Castro J, Ordonez A, Isla D, Sanchez A, Arrivi A, Manzano J L, M.G. Baron. Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study. Cancer Chemother Pharmacol 2006; [Epub ahead of print].
  33. Ordóñez A, González-Barón M, De Castro J, Isla D, Sanchez A, Arrivi A, et al. Epoetin beta (NeoRecormon®) prevents anaemia improves quality of life in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer. 2005;49(Suppl. 2):S339;(abstract P-836)
  34. Barrett-Lee PJ, Bailey NP, O’Brien MER, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000;82:93–97
  35. Henry DH, Brooks BJ, Case DC, Fishkin E, Jacobson R, Keller AM, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am. 1995;1:252–260
  36. Spaëth D, Salles G, Facon T, Garidi R, Vaida I, Fiorentini P, et al. Epoetin beta 30000IU once weekly is effective and well tolerated in anemic patients with solid or non-myeloid hematological malignancies receiving chemotherapy: results from the NAUTICA study. Haematologica/Hematol J. 2006;91(Suppl. 1):7;(abstract 0017)
  37. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–714

PII: S0169-5002(06)00529-0

doi: 10.1016/j.lungcan.2006.09.020

Lung Cancer
Volume 55, Issue 1 , Pages 89-94 , January 2007

Article Tools

* Image Usage & Resolution